On the discovery, biological effects, and use of cisplatin and metallocenes in anticancer chemotherapy

Bioinorganic Chemistry and Applications

Volumn 2012, Issue , 2012, Pages

  Gómez Ruiz, Santiago ^a   Maksimović Ivanić, Danijela ^b   Mijatović, Sanja ^b   Kaluderović, Goran N ^c  

^a UNIVERSIDAD REY JUAN CARLOS   (Spain)

^b UNIVERSITY OF BELGRADE   (Serbia)

^c MARTIN LUTHER UNIVERSITY HALLE WITTENBERG   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

EID: 84864948285     PISSN: 15653633     EISSN: 1687479X     Source Type: Journal    
DOI: 10.1155/2012/140284     Document Type: Review

References (145)

1. Arnesano F., Natile G., Mechanistic insight into the cellular uptake and processing of cisplatin 30 years after its approval by FDA Coordination Chemistry Reviews 2009 253 15-16 2070 2081
2. Higby D. J., Wallace H. J., Albert D. J., Holland J. F., Diaminodichloroplatinum: A phase I study showing responses in testicular and other tumors Cancer 1974 33 5 1219 1225
3. Hambley T. W., Developing new metal-based therapeutics: challenges and opportunities Dalton Transactions 2007 21 43 4929 4937 (Pubitemid 350015417)
4. Jamieson E. R., Lippard S. J., Structure, recognition, and processing of cisplatin-DNA adducts Chemical Reviews 1999 99 9 2467 2498
5. Giaccone G., Clinical perspectives on platinum resistance Drugs 2000 59 4 9 17. discussion 37-38 (Pubitemid 30344987)
6. Fuertes M. A., Alonso C., Pérez J. M., Biochemical modulation of cisplatin mechanisms of action: enhancement of antitumor activity and circumvention of drug resistance Chemical Reviews 2003 103 3 645 662
7. Kberle B., Masters J. R. W., Hartley J. A., Wood R. D., Defective repair of cisplatin-induced DNA damage caused by reduced XPA protein in testicular germ cell tumours Current Biology 1999 9 5 273 276 (Pubitemid 29139312)
8. Mamenta E. L., Poma E. E., Kaufmann W. K., Delmastro D. A., Grady H. L., Chaney S. G., Enhanced replicative bypass of platinum-DNA adducts in cisplatin-resistant human ovarian carcinoma cell lines Cancer Research 1994 54 13 3500 3505 (Pubitemid 24225973)
9. Eliopoulos A. G., Kerr D. J., Herod J., Hodgkins L., Krajewski S., Reed J. C., Young L. S., The control of apoptosis and drug resistance in ovarian cancer: influence of p53 and Bcl-2 Oncogene 1995 11 7 1217 1228
10. Ivanov A. I., Christodoulou J., Parkinson J. A., Barnham K. J., Tucker A., Woodrow J., Sadler P. J., Cisplatin binding sites on human albumin The Journal of Biological Chemistry 1998 273 24 14721 14730 (Pubitemid 28272756)
11. DeConti R. C., Toftness B. R., Lange R. C., Creasey W. A., Clinical and pharmacological studies with cis diamminedichloroplatinum(II) Cancer Research 1973 33 6 1310 1315
12. Gately D. P., Howell S. B., Cellular accumulation of the anticancer agent cisplatin: A review British Journal of Cancer 1993 67 6 1171 1176 (Pubitemid 23172848)
13. Ishida S., Lee J., Thiele D. J., Herskowitz I., Uptake of the anticancer drug cisplatin mediated by the copper transporter Ctr1 in yeast and mammals Proceedings of the National Academy of Sciences of the United States of America 2002 99 22 14298 14302 (Pubitemid 35257666)
14. Alderden R. A., Hall M. D., Hambley T. W., The discovery and development of cisplatin Journal of Chemical Education 2006 83 5 728 734
15. Timerbaev A. R., Hartinger C. G., Aleksenko S. S., Keppler B. K., Interactions of antitumor metallodrugs with serum proteins: Advances in characterization using modern analytical methodology Chemical Reviews 2006 106 6 2224 2248
16. Volckova E., Evanics F., Yang W. W., Bose R. N., Unwinding of DNA polymerases by the antitumor drug, cis-diamminedichloroplatinum(II) Chemical Communications 2003 9 10 1128 1129 (Pubitemid 36606237)
17. Ahmad S., Platinum-DNA interactions and subsequent cellular processes controlling sensitivity to anticancer platinum complexes Chemistry and Biodiversity 2010 7 3 543 566
18. Knox R. J., Friedlos F., Lydall D. A., Roberts J. J., Mechanism of cytotoxicity of anticancer platinum drugs: evidence that cis- diamminedichloroplatinum(II) and cis-diammine-(1,1-cyclobutanedicarboxylato) platinum(II) differ only in the kinetics of their interaction with DNA Cancer Research 1986 46 4 1972 1979 (Pubitemid 16080411)
19. Munchausen L. L., Rahn R. O., Physical studies on the binding of cis dichlorodiamine platinum(II) to DNA and homopolynucleotides Biochimica et Biophysica Acta 1975 414 3 242 255
20. Eastman A., Characterization of the adducts produced in DNA by cis-diamminedichloroplatinum(II) and cis-dichloro(ethylenediamine)platinum(II) Biochemistry 1983 22 16 3927 3933 (Pubitemid 13035562)
21. Plooy A. C. M., Fichtinger-Schepman A. M. J., Schutte H. H., The quantitative detection of various Pt-DNA-adducts in Chinese hamster ovary cells treated with cisplatin: Application of immunochemical techniques Carcinogenesis 1985 6 4 561 566 (Pubitemid 15101787)
22. Egger A. E., Hartinger C. G., Hamidane H. B., Tsybin Y. O., Keppler B. K., Dyson P. J., High resolution mass spectrometry for studying the interactions of cisplatin with oligonucleotides Inorganic Chemistry 2008 47 22 10626 10633
23. Zamble D. B., Mu D., Reardon J. T., Sancar A., Lippard S. J., Repair of cisplatin-DNA adducts by the mammalian excision nuclease Biochemistry 1996 35 31 10004 10013 (Pubitemid 26269915)
24. Reardon J. T., Vaisman A., Chaney S. G., Sancar A., Efficient nucleotide excision repair of cisplatin, oxaliplatin, and bis- acetoammine-dichloro- cyclohexylamine-platinum(IV) (JM216) platinum intrastrand DNA diadducts Cancer Research 1999 59 16 3968 3971 (Pubitemid 29393563)
25. Johnson S. W., Perez R. P., Godwin A. K., Yeung A. T., Handel L. M., Ozols R. F., Hamilton T. C., Role of platinum-DNA adduct formation and removal in cisplatin resistance in human ovarian cancer cell lines Biochemical Pharmacology 1994 47 4 689 697 (Pubitemid 24094274)
26. Ferry K. V., Hamilton T. C., Johnson S. W., Increased nucleotide excision repair in cisplatin-resistant ovarian cancer cells: role of ERCC1-XPF Biochemical Pharmacology 2000 60 9 1305 1313
27. Fink D., Zheng H., Nebel S., Norris P. S., Aebi S., Lin T. P., Nehmé A., Christen R. D., Haas M., MacLeod C. L., Howell S. B., In vitro and in vivo resistance to cisplatin in cells that have lost DNA mismatch repair Cancer Research 1997 57 10 1841 1845 (Pubitemid 27209707)
28. Scheeff E. D., Briggs J. M., Howell S. B., Molecular modeling of the intrastrand guanine-guanine DNA adducts produced by cisplatin and oxaliplatin Molecular Pharmacology 1999 56 3 633 643 (Pubitemid 29406890)
29. Vaisman A., Varchenko M., Umar A., Kunkel T. A., Risinger J. I., Barrett J. C., Hamilton T. C., Chaney S. G., The role of hMLH1, hMSH3, and hMSH6 defects in cisplatin and oxaliplatin resistance: correlation with replicative bypass of platinum-DNA adducts Cancer Research 1998 58 16 3579 3585 (Pubitemid 28376554)
30. Chaney S. G., Campbell S. L., Bassett E., Wu Y., Recognition and processing of cisplatin- and oxaliplatin-DNA adducts Critical Reviews in Oncology/Hematology 2005 53 1 3 11 (Pubitemid 39656106)
31. Cepeda V., Fuertes M. A., Castilla J., Alonso C., Quevedo C., Pérez J. M., Biochemical mechanisms of cisplatin cytotoxicity Anti-Cancer Agents in Medicinal Chemistry 2007 7 1 3 18 (Pubitemid 46062402)
32. Henkels K. M., Turchi J. J., Induction of apoptosis in cisplatin-sensitive and -resistant human ovarian cancer cell lines Cancer Research 1997 57 20 4488 4492 (Pubitemid 27441050)
33. Wang D., Lippard S. J., Cellular processing of platinum anticancer drugs Nature Reviews Drug Discovery 2005 4 4 307 320 (Pubitemid 41130944)
34. Juo Z. S., Chiu T. K., Leiberman P. M., Baikalov I., Berk A. J., Dickerson R. E., How proteins recognize the TATA box Journal of Molecular Biology 1996 261 2 239 254 (Pubitemid 26275806)
35. Yaneva J., Leuba S. H., Van Holde K., Zlatanova J., The major chromatin protein his tone H1 binds preferentially to cis-platinum-damaged DNA Proceedings of the National Academy of Sciences of the United States of America 1997 94 25 13448 13451
36. Kartalou M., Samson L. D., Essigmann J. M., Cisplatin adducts inhibit 1,N6-ethenoadenine repair by interacting with the human 3-methyladenine DNA glycosylase Biochemistry 2000 39 27 8032 8038 (Pubitemid 30452378)
37. Sti C., Rcz A., Csermely P., A nucleotide-dependent molecular switch controls ATP binding at the C-terminal domain of Hsp90. N-terminal nucleotide binding unmasks a C-terminal binding pocket The Journal of Biological Chemistry 2002 277 9 7066 7075 (Pubitemid 34953095)
38. Peleg-Shulman T., Gibson D., Cisplatin-protein adducts are efficiently removed by glutathione but not by 5′-guanosine monophosphate Journal of the American Chemical Society 2001 123 13 3171 3172 (Pubitemid 32879599)
39. Daino H., Matsumura I., Takada K., Odajima J., Tanaka H., Ueda S., Shibayama H., Ikeda H., Hibi M., Machii T., Hirano T., Kanakura Y., Induction of apoptosis by extracellular ubiquitin in human hematopoietic cells: possible involvement of STAT3 degradation by proteasome pathway in interleukin 6-dependent hematopoietic cells Blood 2000 95 8 2577 2585 (Pubitemid 30210536)
40. Nguewa P. A., Fuertes M. A., Cepeda V., Iborra S., Carrin J., Valladares B., Alonso C., Pérez J. M., Pentamidine is an antiparasitic and apoptotic drug that selectively modifies ubiquitin Chemistry and Biodiversity 2005 2 10 1387 1400 (Pubitemid 41655606)
41. Maksimovic-Ivanic D., Mijatovic S., Miljkovic D., Harhaji-Trajkovic L., Timotijevic G., Mojic M., Dabideen D., Cheng K. F., McCubrey J. A., Mangano K., Al-Abed Y., Libra M., Garotta G., Stosic-Grujicic S., Nicoletti F., The antitumor properties of a nontoxic, nitric oxide-modified version of saquinavir are independent of Akt Molecular Cancer Therapeutics 2009 8 5 1169 1178
42. Casini A., Gabbiani C., Mastrobuoni G., Pellicani R. Z., Intini F. P., Arnesano F., Natile G., Moneti G., Francese S., Messori L., Insights into the molecular mechanisms of protein platination from a case study: the reaction of anticancer platinum(II) iminoethers with horse heart cytochrome C Biochemistry 2007 46 43 12220 12230 (Pubitemid 350022376)
43. Arnesano F., Natile G., Platinum on the road: interactions of antitumoral cisplatin with proteins Pure and Applied Chemistry 2008 80 12 2715 2725
44. Datta S. R., Brunet A., Greenberg M. E., Cellular survival: A play in three akts Genes and Development 1999 13 22 2905 2927
45. Fraser M., Leung B. M., Yan X., Dan H. C., Cheng J. Q., Tsang B. K., p53 is a determinant of X-linked inhibitor of apoptosis protein/Akt-mediated chemoresistance in human ovarian cancer cells Cancer Research 2003 63 21 7081 7088 (Pubitemid 37413443)
46. Dan H. C., Sun M., Kaneko S., Feldman R. I., Nicosia S. V., Wang H. G., Tsang B. K., Cheng J. Q., Akt phosphorylation and stabilization of X-linked inhibitor of apoptosis protein (XIAP) The Journal of Biological Chemistry 2004 279 7 5405 5412 (Pubitemid 38220563)
47. Viniegra J. G., Losa J. H., Snchez-Arévalo V. J., Cobo C. P., Soria V. M. F., Ramn y Cajal S., Snchez-Prieto R., Modulation of PI3K/Akt pathway by E1a mediates sensitivity to cisplatin Oncogene 2002 21 46 7131 7136 (Pubitemid 35252988)
48. Shaul Y., c-Abl: Activation and nuclear targets Cell Death and Differentiation 2000 7 1 10 16 (Pubitemid 30153759)
49. Gong J., Costanzo A., Yang H. Q., Mellno G., Kaelin W. G., Levrero M., Wang J. Y. J., The tyrosine kinase c-Abl regulates p73 in apoptotic response to cisplatin-induced DNA damage Nature 1999 399 6738 806 809 (Pubitemid 29293179)
50. Harhaji-Trajkovic L., Vilimanovich U., Kravic-Stevovic T., Bumbasirevic V., Trajkovic V., AMPK-mediated autophagy inhibits apoptosis in cisplatin-treated tumour cells Journal of Cellular and Molecular Medicine 2009 13 9 3644 3654
51. Wang X., Martindale J. L., Holbrook N. J., Requirement for ERK activation in cisplatin-induced apoptosis The Journal of Biological Chemistry 2000 275 50 39435 39443 (Pubitemid 32058968)
52. Cui W., Yazlovitskaya E. M., Mayo M. S., Cisplatin-induced response of c-jun N-terminal kinase 1 and extracellular signalregulated protein kinases 1 and 2 in a series of cisplatin-resistant ovarian carcinoma cell lines Molecular Carcinogenesis 2000 29 219 228 (Pubitemid 32052666)
53. Mijatovic S., Maksimovic-Ivanic D., Radovic J., Miljkovic D., Kaludjerovic G. N., Sabo T. J., Trajkovic V., Aloe emodin decreases the ERK-dependent anticancer activity of cisplatin Cellular and Molecular Life Sciences 2005 62 11 1275 1282 (Pubitemid 40880131)
54. Mijatovic S., Maksimovic-Ivanic D., Radovic J., Miljkovic D., Harhaji L., Vuckovic O., Stosic-Grujicic S., Mostarica Stojkovic M., Trajkovic V., Anti-glioma action of aloe emodin: the role of ERK inhibition Cellular and Molecular Life Sciences 2005 62 5 589 598 (Pubitemid 40386337)
55. Mansouri A., Ridgway L. D., Korapati A. L., Zhang Q., Tian L., Wang Y., Siddik Z. H., Mills G. B., Claret F. X., Sustained activation of JNK/p38 MAPK pathways in response to cisplatin leads to Fas ligand induction and cell death in ovarian carcinoma cells The Journal of Biological Chemistry 2003 278 21 19245 19256 (Pubitemid 36799316)
56. Snchez-Perez I., Murgua J. R., Perona R., Cisplatin induces a persistent activation of JNK that is related to cell death Oncogene 1998 16 4 533 540 (Pubitemid 28062081)
57. Hayakawa J., Ohmichi M., Kurachi H., Ikegami H., Kimura A., Matsuoka T., Jikihara H., Mercola D., Murata Y., Inhibition of extracellular signal-regulated protein kinase or c-Jun N- terminal protein kinase cascade, differentially activated by cisplatin, sensitizes human ovarian cancer cell line The Journal of Biological Chemistry 1999 274 44 31648 31654
58. Davis R. J., Signal transduction by the JNK group of MAP kinases Cell 2000 103 2 239 252
59. Pandey P., Raingeaud J., Kaneki M., Weichselbaum R., Davis R. J., Kufe D., Kharbanda S., Activation of p38 mitogen-activated protein kinase by c-Abl-dependent and -independent mechanisms The Journal of Biological Chemistry 1996 271 39 23775 23779 (Pubitemid 26327347)
60. Hernndez Losa J., Parada Cobo C., Guinea Viniegra J., Snchez-Arevalo Lobo V. J., Ramn y Cajal S., Snchez-Prieto R., Role of the p38 MAPK pathway in cisplatin-based therapy Oncogene 2003 22 26 3998 4006
61. Wang D., Lippard S. J., Cisplatin-induced post-translational modification of histones H3 and H4 The Journal of Biological Chemistry 2004 279 20 20622 20625 (Pubitemid 38656456)
62. Gonzalez V. M., Fuertes M. A., Alonso C., Perez J. M., Is cisplatin-induced cell death always produced by apoptosis? Molecular Pharmacology 2001 59 4 657 663 (Pubitemid 32273993)
63. Lieberthal W., Triaca V., Levine J., Mechanisms of death induced by cisplatin in proximal tubular epithelial cells: Apoptosis vs. necrosis American Journal of Physiology 1996 270 4 F700 F708
64. Eguchi Y., Shimizu S., Tsujimoto Y., Intracellular ATP levels determine cell death fate by apoptosis or necrosis Cancer Research 1997 57 10 1835 1840 (Pubitemid 27209706)
65. Zhou R., Vander Heiden M. G., Rudin C. M., Genotoxic exposure is associated with alterations in glucose uptake and metabolism Cancer Research 2002 62 12 3515 3520 (Pubitemid 34651402)
66. Herceg Z., Wang Z. Q., Failure of poly(ADP-ribose) polymerase cleavage by caspases leads to induction of necrosis and enhanced apoptosis Molecular and Cellular Biology 1999 19 7 5124 5133 (Pubitemid 29289550)
67. Hirsch T., Marchetti P., Susin S. A., Dallaporta B., Zamzami N., Marzo I., Geuskens M., Kroemer G., The apoptosis-necrosis paradox. Apoptogenic proteases activated after mitochondrial permeability transition determine the mode of cell death Oncogene 1997 15 13 1573 1581 (Pubitemid 27464650)
68. Ding L., Yuan C., Wei F., Cisplatin restores TRAIL apoptotic pathway in glioblastoma-derived stem cells through up-regulation of DR5 and down-regulation of c-FLIP Cancer Investigation 2011 29 511 520
69. Vondlov Blanrov O., Jelnkov I., Szor A., Skender B., Soucek K., Horvth V., Vaculov A., Andera L., Sova P., Szllosi J., Hofmanov J., Vereb G., Kozubk A., Cisplatin and a potent platinum(IV) complex-mediated enhancement of TRAIL-induced cancer cells killing is associated with modulation of upstream events in the extrinsic apoptotic pathway Carcinogenesis 2011 32 1 42 51
70. Maksimovic-Ivanic D., Stosic-Grujicic S., Nicoletti F., Mijatovic S., Resistance to TRAIl and how to surmount it Immunology Research 2012 52 1-2 157 168
71. Decatris M. P., Sundar S., O'Byrne K. J., Platinum-based chemotherapy in metastatic breast cancer: current status Cancer Treatment Reviews 2004 30 1 53 81 (Pubitemid 38240088)
72. Shelley M. D., Burgon K., Mason M. D., Treatment of testicular germ-cell cancer: A cochrane evidence-based systematic review Cancer Treatment Reviews 2002 28 5 237 253 (Pubitemid 35439438)
73. Kim M. S., Blake M., Baek J. H., Kohlhagen G., Pommier Y., Carrier F., Inhibition of histone deacetylase increases cytotoxicity to anticancer drugs targeting DNA Cancer Research 2003 63 21 7291 7300 (Pubitemid 37413470)
74. Long N. J., Metallocenes 1998 Oxford, UK Blackwell Science
75. Korfel A., Scheulen M. E., Schmoll H. J., Grndel O., Harstrick A., Knoche M., Fels L. M., Skorzec M., Bach F., Baumgart J., Sa G., Seeber S., Thiel E., Berdel W. E., Phase I clinical and pharmacokinetic study of titanocene dichloride in adults with advanced solid tumors Clinical Cancer Research 1998 4 11 2701 2708 (Pubitemid 28523495)
76. Christodoulou C. V., Ferry D. R., Fyfe D. W., Young A., Doran J., Sheehan T. M. T., Eliopoulos A., Hale K., Baumgart J., Sass G., Kerr D. J., Phase I trial of weekly scheduling and pharmacokinetics of titanocene dichloride in patients with advanced cancer Journal of Clinical Oncology 1998 16 8 2761 2769 (Pubitemid 28363042)
77. Mross K., Robben-Bathe P., Edler L., Baumgart J., Berdel W. E., Fiebig H., Unger C., Phase I clinical trial of a day-1, -3, -5 every 3 weeks schedule with titanocene dichloride (MKT 5) in patients with advanced cancer: A study of the phase I study group of the association for medical oncology (AIO) of the German Cancer Society Onkologie 2000 23 6 576 579 (Pubitemid 32046056)
78. Mller B. W., Mller R., Lucks S., Mohr W., Medac Gesellschaft fur Klinische Spzeilprparate GmbH. US Patent 5, 296, 237, 1994
79. Krger N., Kleeberg U. R., Mross K., Edler L., Sa G., Hossfeld D. K., Phase II clinical trial of titanocene dichloride in patients with metastatic breast cancer Onkologie 2000 23 1 60 62 (Pubitemid 30154851)
80. Lmmen G., Sperling H., Luboldt H., Otto T., Rbben H., Phase II trial of titanocene dichloride in advanced renal-cell carcinoma Cancer Chemotherapy and Pharmacology 1998 42 5 415 417 (Pubitemid 28430373)
81. Meléndez E., Titanium complexes in cancer treatment Critical Reviews in Oncology/Hematology 2002 42 3 309 315 (Pubitemid 34615691)
82. Caruso F., Rossi M., Sigel A., Sigel H., Antitumor titanium compounds and related metallocenes Metal Ions in Biological System 2004 42 New York, NY, USA Marcel Dekker Metal Complexes in Tumor Diagnostics and as Anticancer Agents
83. Dabrowiak J. C., Metals in Medicine 2009 West Sussex, UK John Wiley Sons
84. Olszewski U., Hamilton G., Mechanisms of cytotoxicity of anticancer titanocenes Anti-Cancer Agents in Medicinal Chemistry 2010 10 4 302 311
85. Strohfeldt K., Tacke M., Bioorganometallic fulvene-derived titanocene anti-cancer drugs Chemical Society Reviews 2008 37 6 1174 1187
86. Hernndez R., Lamboy J., Gao L. M., Matta J., Romn F. R., Meléndez E., Structure-activity studies of Ti(IV) complexes: Aqueous stability and cytotoxic properties in colon cancer HT-29 cells Journal of Biological Inorganic Chemistry 2008 13 5 685 692
87. Hernndez R., Méndez J., Lamboy J., Torres M., Romn F. R., Meléndez E., Titanium(IV) complexes: cytotoxicity and cellular uptake of titanium(IV) complexes on caco-2 cell line Toxicology in Vitro 2010 24 1 178 183
88. Gao L. M., Matta J., Rheingold A. L., Meléndez E., Synthesis, structure and biological activity of amide-functionalized titanocenyls: improving their cytotoxic properties Journal of Organometallic Chemistry 2009 694 26 4134 4139
89. Gansuer A., Winkler I., Worgull D., Lauterbach T., Franke D., Selig A., Wagner L., Prokop A., Carbonyl-substituted titanocenes: A novel class of cytostatic compounds with high antitumor and antileukemic activity Chemistry 2008 14 14 4160 4163
90. Allen O. R., Croll L., Gott A. L., Knox R. J., McGowan P. C., Functionalized cyclopentadienyl titanium organometallic compounds as new antitumor drugs Organometallics 2004 23 2 288 292
91. Allen O. R., Gott A. L., Hartley J. A., Hartley J. M., Knox R. J., McGowan P. C., Functionalised cyclopentadienyl titanium compounds as potential anticancer drugs Dalton Transactions 2007 43 5082 5090 (Pubitemid 350015430)
92. Potter G. D., Baird M. C., Cole S. P. C., A new series of titanocene dichloride derivatives bearing chiral alkylammonium groups; Assessment of their cytotoxic properties Inorganica Chimica Acta 2010 364 1 16 22
93. Gao L. M., Vera J. L., Matta J., Meléndez E., Synthesis and cytotoxicity studies of steroid-functionalized titanocenes as potential anticancer drugs: sex steroids as potential vectors for titanocenes Journal of Biological Inorganic Chemistry 2010 15 6 851 859
94. Gómez-Ruiz S., Kaluerovi G. N., Prashar S., Polo-Cern D., Fajardo M., iak., Sabo T. J., Jurani Z. D., Cytotoxic studies of substituted titanocene and ansa-titanocene anticancer drugs Journal of Inorganic Biochemistry 2008 102 8 1558 1570
95. Gómez-Ruiz S., Kaluerovi G. N., iak., Besu I., Jurani Z. D., Prashar S., Fajardo M., Anticancer drugs based on alkenyl and boryl substituted titanocene complexes Journal of Organometallic Chemistry 2009 694 13 1981 1987
96. Kaluerovi G. N., Tayurskaya V., Paschke R., Prashar S., Fajardo M., Gómez-Ruiz S., Synthesis, characterization and biological studies of alkenyl-substituted titanocene(IV) carboxylate complexes Applied Organometallic Chemistry 2010 24 9 656 662
97. Sun H., Li H., Weir R. A., Sadler P. J., You have full text access to this content the first specific Ti IV -protein complex: potential relevance to anticancer activity of titanocenes Angewandte Chemie International Edition 1998 37 11 1577 1579
98. Guo M., Sadler P. J., Competitive binding of the anticancer drug titanocene dichloride to N,N′-ethylenebis(o-hydroxyphenylglycine) and adenosine triphosphate: A model for Ti IV uptake and release by transferrin Journal of the Chemical Society, Dalton Transactions 2000 1 7 9
99. Guo M., Sun H., Bihari S., Parkinson J. A., Gould R. O., Parsons S., Sadler P. J., Stereoselective formation of seven-coordinate titanium(IV) monomer and dimer complexes of ethylenebis(o-hydroxyphenyl)glycine Inorganic Chemistry 2000 39 2 206 215
100. Guo M., Sun H., McArdle H. J., Gambling L., Sadler P. J., Ti(IV) uptake and release by human serum transferrin and recognition of Ti(IV)-transferrin by cancer cells: understanding the mechanism of action of the anticancer drug titanocene dichloride Biochemistry 2000 39 33 10023 10033 (Pubitemid 30663023)
101. Kpf-Maier P., Krahl D., Tumor inhibition by metallogenes: ultrastructural localization of titanium and vanadium in treated tumor cells by electron energy loss spectroscopy Chemico-Biological Interactions 1983 44 3 317 328 (Pubitemid 13031232)
102. Kpf-Maier P., Intracellular localization of titanium within xenografted sensitive human tumors after treatment with the antitumor agent titanocene dichloride Journal of Structural Biology 1990 105 13 35 45
103. Tinoco A. D., Incarvito C. D., Valentine A. M., Calorimetric, spectroscopic, and model studies provide insight into the transport of Ti(IV) by human serum transferrin Journal of the American Chemical Society 2007 129 11 3444 3454 (Pubitemid 46449376)
104. Tinoco A. D., Eames E. V., Valentine A. M., Reconsideration of serum Ti(IV) transport: Albumin and transferrin trafficking of Ti(IV) and its complexes Journal of the American Chemical Society 2008 130 7 2262 2270 (Pubitemid 351288003)
105. Pavlaki M., Debeli K., Triantaphyllidou I. E., Klouras N., Giannopoulou E., Aletras A. J., A proposed mechanism for the inhibitory effect of the anticancer agent titanocene dichloride on tumour gelatinases and other proteolytic enzymes Journal of Biological Inorganic Chemistry 2009 14 6 947 957
106. Allen O. R., Knox R. J., McGowan P. C., Functionalised cyclopentadienyl zirconium compounds as potential anticancer drugs Dalton Transactions 2008 39 5293 5295
107. Wallis D., Claffey J., Gleeson B., Hogan M., Mller-Bunz H., Tacke M., Novel zirconocene anticancer drugs? Journal of Organometallic Chemistry 2009 694 6 828 833
108. Gómez-Ruiz S., Kaluderovi G. N., Polo-Cern D., Tayurskaya V., Prashar S., Fajardo M., Paschke R., A novel alkenyl-substituted ansa-zirconocene complex with dual application as olefin polymerization catalyst and anticancer drug Journal of Organometallic Chemistry 2009 694 18 3032 3038
109. Kpf-Maier P., Keppler B. K., Antitumor bis(cyclopentadienyl) metal complexes Metal Complexes in Cancer Chemotherapy 1993 Weinheim, Germany VCH Verlagsgesellschaft 259 296
110. Navara C. S., Benyumov A., Vassilev A., Narla R. K., Ghosh P., Uckun F. M., Vanadocenes as potent anti-proliferative agents disrupting mitotic spindle formation in cancer cells Anti-Cancer Drugs 2001 12 4 369 376 (Pubitemid 32453443)
111. Ghosh P., D'Cruz O. J., Narla R. K., Uckun F. M., Apoptosis-inducing vanadocene compounds against human testicular cancer Clinical Cancer Research 2000 6 4 1536 1545 (Pubitemid 30226244)
112. Palkov H., Vinklrek J., Holubov J., Csaov I., Erben M., The interaction of antitumor active vanadocene dichloride with sulfur-containing amino acids Journal of Organometallic Chemistry 2007 692 17 3758 3764 (Pubitemid 47042823)
113. Vinklrek J., Honzek J., Holubov J., Interaction of the antitumor agent vanadocene dichloride with phosphate buffered saline Inorganica Chimica Acta 2004 357 12 3765 3769
114. Vinklrek J., Palkov H., Honzek J., Holubov J., Holapek M., Csaov I., Investigation of vanadocene(IV) -amino acid complexes: synthesis, structure, and behavior in physiological solutions, human plasma, and blood Inorganic Chemistry 2006 45 5 2156 2162
115. Gleeson B., Claffey J., Deally A., Hogan M., Méndez L. M. M., Mller-Bunz H., Patil S., Wallis D., Tacke M., Synthesis and cytotoxicity studies of fluorinated derivatives of vanadocene Y European Journal of Inorganic Chemistry 2009 19 2804 2810
116. Gleeson B., Claffey J., Hogan M., Mller-Bunz H., Wallis D., Tacke M., Novel benzyl-substituted vanadocene anticancer drugs Journal of Organometallic Chemistry 2009 694 9-10 1369 1374
117. Gleeson B., Claffey J., Deally A., Hogan M., Méndez L. M. M., Mller-Bunz H., Patil S., Tacke M., Novel benzyl-substituted molybdocene anticancer drugs Inorganica Chimica Acta 2010 363 8 1831 1836
118. Gleeson B., Hogan M., Mller-Bunz H., Tacke M., Synthesis and preliminary cytotoxicity studies of indole-substituted vanadocenes Transition Metal Chemistry 2010 35 8 973 983
119. Honzek J., Klepalov I., Vinklrek J., Padlkov Z., Csaov I., iman P., ezov M., Synthesis, characterization and cytotoxic effect of ring-substituted and ansa-bridged vanadocene complexes Inorganica Chimica Acta 2011 373 1 1 7
120. Waern J. B., Harding M. M., Bioorganometallic chemistry of molybdocene dichloride Journal of Organometallic Chemistry 2004 689 25 4655 4668 (Pubitemid 40090416)
121. Waern J. B., Dillon C. T., Harding M. M., Organometallic anticancer agents: cellular uptake and cytotoxicity studies on thiol derivatives of the antitumor agent molybdocene dichloride Journal of Medicinal Chemistry 2005 48 6 2093 2099 (Pubitemid 40396336)
122. Waern J. B., Harris H. H., Lai B., Cai Z., Harding M. M., Dillon C. T., Intracellular mapping of the distribution of metals derived from the antitumor metallocenes Journal of Biological Inorganic Chemistry 2005 10 5 443 452 (Pubitemid 41400733)
123. Waern J. B., Turner P., Harding M. M., Synthesis and hydrolysis of thiol derivatives of molybdocene dichloride incorporating electron-withdrawing substituents Organometallics 2006 25 14 3417 3421 (Pubitemid 44146192)
124. Campbell K. S., Foster A. J., Dillon C. T., Harding M. M., Genotoxicity and transmission electron microscopy studies of molybdocene dichloride Journal of Inorganic Biochemistry 2006 100 7 1194 1198 (Pubitemid 43818119)
125. Toney J. H., Marks T. J., Hydrolysis chemistry of the metallocene dichlorides M( 5 -C 5 H 5) 2 Cl 2, M=Ti, V, Zr. Aqueous kinetics, equilibria, and mechanistic implications for a new class of antitumor agents Journal of the American Chemical Society 1985 107 4 947 953 (Pubitemid 15140056)
126. Balzarek C., Weakley T. J. R., Kuo L. Y., Tyler D. R., Investigation of the monomer-dimer equilibria of molybdocenes in water Organometallics 2000 19 15 2927 2931
127. Kuo L. Y., Kanatzidis M. G., Sabat M., Tipton A. L., Marks T. J., Metallocene antitumor agents. Solution and solid-state molybdenocene coordination chemistry of DNA constituents Journal of the American Chemical Society 1991 113 24 9027 9045
128. Abeysinghe P. M., Harding M. M., Antitumour bis(cyclopentadienyl) metal complexes: titanocene and molybdocene dichloride and derivatives Dalton Transactions 2007 32 3474 3482 (Pubitemid 47222535)
129. Harding M. M., Mokdsi G., Antitumour metallocenes: structure-activity studies and interactions with biomolecules Current Medicinal Chemistry 2000 7 12 1289 1303
130. Campbell K. S., Dillon C. T., Smith S. V., Harding M. M., Radiotracer studies of the antitumor metallocene molybdocene dichloride with biomolecules Polyhedron 2007 26 2 456 459
131. Kpf-Maier P., Kpf H., Neuse E. W., Ferrocenium saltsthe first antineoplastic iron compounds Angewandte ChemieInternational Edition in English 1984 23 6 456 457 (Pubitemid 14068493)
132. Kpf-Maier P., Kopf H., Neuse E. W., Ferricenium complexes: A new type of water-soluble antitumor agent Journal of Cancer Research and Clinical Oncology 1984 108 3 336 340 (Pubitemid 15211814)
133. Top S., Tang J., Vessires A., Carrez D., Provot C., Jaouen G., Ferrocenyl hydroxytamoxifen: A prototype for a new range of oestradiol receptor site-directed cytotoxics Chemical Communications 1996 8 955 956 (Pubitemid 26139585)
134. Top S., Dauer B., Vaissermann J., Jaouen G., Facile route to ferrocifen, 1-[4-(2-dimethylaminoethoxy)]-1-(phenyl-2-ferrocenyl-but-1-ene), first organometallic analogue of tamoxifen, by the McMurry reaction Journal of Organometallic Chemistry 1997 541 1-2 355 361 (Pubitemid 127163043)
135. Top S., Vessires A., Cabestaing C., Laios I., Leclercq G., Provot C., Jaouen G. E., Studies on organometallic selective estrogen receptor modulators. (SERMs) Dual activity in the hydroxy-ferrocifen series Journal of Organometallic Chemistry 2001 637639 1 500 506 (Pubitemid 33376825)
136. Top S., Vessires A., Leclercq G., Quivy J., Tang J., Vaissermann J., Huché M., Jaouen G., Synthesis, biochemical properties and molecular modelling studies of organometallic Specific Estrogen Receptor Modulators (SERMs), the ferrocifens and hydroxyferrocifens: evidence for an antiproliferative effect of hydroxyferrocifens on both hormone-dependent and hormone-independent breast cancer cell lines Chemistry 2003 9 21 5223 5236
137. Jaouen G., Top S., Vessires A., Leclercq G., McGlinchey M. J., The first organometallic selective estrogen receptor modulators (SERMs) and their relevance to breast cancer Current Medicinal Chemistry 2004 11 18 2505 2517 (Pubitemid 39177414)
138. Plazuk D., Vessires A., Hillard E. A., Buriez O., Labbé E., Pigeon P., Plamont M. A., Amatore C., Zakrzewski J., Jaouen G., A [3]ferrocenophane polyphenol showing a remarkable antiproliferative activity on breast and prostate cancer cell lines Journal of Medicinal Chemistry 2009 52 15 4964 4967
139. Hillard E. A., Vessires A., Jaouen G., Ferrocene functionalized endocrine modulators as anticancer agents Topics in Organometallic Chemistry 2010 32 81 117
140. Buck D. P., Abeysinghe P. M., Cullinane C., Day A. I., Collins J. G., Harding M. M., Inclusion complexes of the antitumour metallocenes Cp 2 MCl 2 (M=Mo, Ti) with cucurbit[n]urils Dalton Transactions 2008 17 2328 2334 (Pubitemid 351537811)
141. Pereira C. C. L., Diogo C. V., Burgeiro A., Oliveira P. J., Marques M. P. M., Braga S. S., Almeida Paz F. A., Pillinger M., Gonalves I. S., Complex formation between heptakis(2,6-di-O-methyl)- -cyclodextrin and cyclopentadienyl molybdenum(II) dicarbonyl complexes: structural studies and cytotoxicity evaluations Organometallics 2008 27 19 4948 4956
142. Pérez-Quintanilla D., Gomez-Ruiz S., iak., Sierra I., Prashar S., Del Hierro I., Fajardo M., Juranic Z. D., Kaluderovic G. N., A new generation of anticancer drugs: mesoporous materials modified with titanocene complexes Chemistry 2009 15 22 5588 5597
143. Kaluerovi G. N., Pérez-Quintanilla D., Sierra I., Prashar S., Hierro I. D., Iak E., Jurani Z. D., Fajardo M., Gómez-Ruiz S., Study of the influence of the metal complex on the cytotoxic activity of titanocene-functionalized mesoporous materials Journal of Materials Chemistry 2010 20 4 806 814
144. Kaluerovi G. N., Pérez-Quintanilla D., iak., Jurani Z. D.,
145. Garca-Peas A., Gómez-Ruiz S., Pérez-Quintanilla D., Study of the cytotoxicity and particle action in human cancer cells of titanocene-functionalized materials Journal of Inorganic Biochemistry 2012 106 2 100 110